Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2018 16:01 ET | Source: Repros Therapeutics Inc.

Repros Announces Negative Opinion From the EMA for Enclomiphene

THE WOODLANDS, Texas, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.®, (Nasdaq:RPRX) ("Repros" or the "Company") today announced that, consistent with the previously disclosed guidance...
December 15, 2017 16:00 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency

THE WOODLANDS, Texas, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (NASDAQ:RPRX) (“Repros” or the “Company”) today announced that following an Oral Explanation, it has received...
December 12, 2017 06:30 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.® Announces Acquisition by Allergan plc

THE WOODLANDS, Texas, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (NASDAQ:RPRX) (“Repros” or the “Company”) today announced that it has entered into a definitive agreement under which...
November 13, 2017 08:45 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results

THE WOODLANDS, Texas, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2017. Financial Results ...
August 14, 2017 09:15 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results

THE WOODLANDS, Texas, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2017. Financial Results Net...
July 17, 2017 06:30 ET | Source: Repros Therapeutics Inc.

Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA

Repros Assessing Uterine Fibroid and Endometriosis Development Program with Vaginal Drug Delivery Treatment Expects to Receive European Patent that Relates to Selective Progesterone...
May 18, 2017 08:45 ET | Source: Repros Therapeutics Inc.

Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock

THE WOODLANDS, Texas, May 18, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc (Nasdaq:RPRX) (“Repros” or the “Company”), announced today that it has entered into an underwriting agreement to sell...
May 17, 2017 16:55 ET | Source: Repros Therapeutics Inc.

Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock

THE WOODLANDS, Texas, May 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) (“Repros” or the “Company”) today announced that it intends to offer primary shares of its common stock...
May 09, 2017 16:01 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results

THE WOODLANDS, Texas, May 09, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2017.Financial Results Net loss...
April 17, 2017 09:15 ET | Source: Repros Therapeutics Inc.

Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions

THE WOODLANDS, Texas, April 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the issuance of a new patent, U.S. Patent number 9,616,074 (the ‘074 patent), that...